Identification of the BCR-ABL gene has led to specific targeting with tyrosine kinase inhibitor imatinib (Gleevec), which has achieved great success in depleting BCR-ABL-positive leukemia cells [57]. This evidence concerns the gene ABL1 and leukemia.